Zonisamide(AD 810 CI 912)

立即咨询

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:	68291-97-4
规格:	≥98%

包装与价格：

包装	价格(元)
50mg	电议
100mg	电议
250mg	电议
500mg	电议
1g	电议
10g	电议

产品介绍

Zonisamide (AD810; CI912; AD-810; CI-912), an antiepileptic drug, is a voltage-dependent sodium channel and T-type calcium channel blocker. Zonisamide is a sulfonamide anticonvulsant approved for use as an adjunctive therapy in adults with partial-onset seizures; infantile spasm, mixed seizure types of Lennox–Gastaut syndrome, myoclonic, and generalized tonic clonic seizure. Zonisamide modifies dopamine (DA) activity, provides protection in ischemia mice models and influences antioxidant systems. Zonisamide attenuates the reduction in striatal contents of DA, its metabolite DOPAC and tyrosine hydroxylase (TH).

理化性质和储存条件

Molecular Weight (MW)	212.23
Formula	C8H8N2O3S
CAS No.	68291-97-4
Storage	-20℃ for 3 years in powder form
Storage	-80℃ for 2 years in solvent
Solubility (In vitro)	DMSO: 42 mg/mL (197.9 mM)
	Water:<1 mg/mL
	Ethanol: 5 mg/mL (23.6 mM)
Other info	Chemical Name: benzo[d]isoxazol-3-ylmethanesulfonamide InChi Key: UBQNRHZMVUUOMG-UHFFFAOYSA-N InChi Code: InChI=1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12) SMILES Code: O=S(CC1=NOC2=CC=CC=C12)(N)=O
Synonyms	AD-810; CI-912; AD810; CI912; AD 810; CI 912

实验参考方法

In Vitro	In vitro activity: Zonisamide inhibits monoamine oxidase B (MAO-B) activity in vitro with an IC(50) of 25 μM.
In Vivo	Zonisamide modifies dopamine (DA) activity, provides protection in ischemia mice models and influences antioxidant systems. Zonisamide attenuates the reduction in striatal contents of DA, its metabolite DOPAC and tyrosine hydroxylase (TH). Zonisamide (10 and 30 mg/kg) produces antihyperalgesic and antiallodynic effects in a dose-dependent manner, these effects are manifested by elevation of the withdrawal threshold in response to a thermal (plantar test) or mechanical (von Frey) stimulus, respectively.. Zonisamide produces antinociceptive effects against acute thermal and mechanical nociception in non-ligated mice. Zonisamide reduces the cortical infarction volume to 6% from 68% in vehicle-treated controls and the striatal volume to 8% from 78% in rats. Zonisamide also reduces neuronal necrosis in 5 hippocampal regions (the dentate gyrus, CA4, CA3, CA1, and the subiculum) in rats. Zonisamide causes increase in the quantity of EAAC-1 protein in hippocampus and cortex and down regulation of the GABA transporter GAT-1 in rats with hippocampal seizures. Zonisamide inhibits both the 50 mM KCl-evoked hippocampal glutamate release (AUC for 60 min) from 9.2 mM to 5.8 mM in urethane-anaesthetized rats, as well as the stimulatory effects of Ca2+ on KCl-evoked hippocampal glutamate release.
Animal model	Mice and rats
Formulation & Dosage	10 and 30 mg/kg
References	Exp Neurol. 2010 Feb;221(2):329-34; Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):107-14.